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Background: Natural killer (NK) cells eliminate virus-infected and tumor cells through the release of perforins and
granzymes; they also produce Interferon gamma (IFN-γ) and Tumor necrosis factor alpha (TNF-α), which induce
apoptosis in target cells. Many tumors express Heme oxygenase 1 (HO-1), and this expression has been associated with
avoiding immunosuppression and apoptosis. In this work, HO-1+ Cervical cancer cell (CCC) lines were pre-treated with
HO-1 inhibitor and we assessed whether this inhibition enhanced the sensitivity of CCC to NK cell activity.
Methods: We assessed the expression of HO-1 in HeLa, SiHa, and C-33A CCC by Flow cytometry (FC). CCC were
pre-treated with SnPP or ZnPP HO-1 inhibitors. After that, NK-92 cells were co-cultured with HeLa, SiHa, and C-33A CCC
pre-treated or not with HO-1 inhibitors, and the expression of IFN-γ, TNF-α, CD107a, Granzyme B, NKp44, NKp46, NKp30,
and NKG2D was evaluated by FC.
Results: CCC lines HeLa, SiHa, and C-33A expressed HO-1. Inhibition of HO-1 in these cells increased the expression of
IFN-γ and TNF-α in CD107a + NK-92 cells. We observed a reduction in the expression of NKG2D, NKp46, and NKp30 in
NK cells co-cultured with HeLa and SiHa cells, and when HeLa and SiHa cells were pre-treated with the HO-1 inhibitors,
the expression of NKG2D and NKp30 in NK cells was restored. We observed a similar effect in NK cells co-cultured with
C-33A cells in NKp30 expression.
Conclusion: Inhibition of HO-1 in CCC induces an increase in IFN-γ and TNF-α production in CD107a + NK-92 cells
and restores NKG2D, NKp46 and NKp30 downmodulation in NK cells.
Keywords: Heme oxygenase 1, NK cells, Cervical cancer cells, IFN-γ, TNF-α, NKp30, NKG2DBackground
Cervical cancer is the third most common cancer among
women worldwide [1] The main risk factor for cervical
cancer is infection with the Human papillomavirus (HPV)
[2,3]. HPV types 16 and 18 are responsible for 70% of
cases [4]. The immune system is responsible for eliminat-
ing tumor cells and infected cells with microorganisms or* Correspondence: pablolazareno@gmail.com
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article, unless otherwise stated.foreign antigens. Natural killer (NK) cells are the major
cells responsible for tumor removal and elimination of in-
fected cells [5]. NK cells constitute between 2 and 18% of
total lymphocytes in peripheral blood and are distributed
in lymphoid as well as in non-lymphoid organs. NK cells
respond to cellular signals triggered by receptor activation
or inhibition; once they interact with their specific target,
if these signals trigger NK cell activation, the release of per-
forins and granzymes induces cellular lysis in target cells
[6]. Another important function of NK cells is the produc-
tion of cytokines, such as Interferon gamma (IFN-γ) and
Tumor necrosis factor alpha (TNF-α); these cytokines alsoCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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recruit and activate other cells of the immune response,
such as monocytes/macrophages, dendritic cells, T cells,
and B cells [7,8]. The production of these cytokines by NK
cells promotes innate and adaptive immunity [9]. The
major activating receptors in NK cells are NGK2D and
Natural cytotoxicity receptors (NCR), that is, NKp30,
NKp44, and NKp46 [10]. These activating receptors
recognize ligands in tumor or infected cells [11]. These
ligands for activating receptors are stress-inducible mol-
ecules and include UL16-binding proteins (ULBP) and
(MHC) class I-related chain A/B (MICA/B) recognized
by NKG2D [12,13]. Other ligands include the poliovirus
to DNAM-1, the HLA-B-associated transcript 3 (BAT-
3), and the B7-H6 molecule, both recognized by NKp30
[14,15]. These ligands are absent in normal cells and
their expression is increased in cancer cells. However,
interaction among immune cells, tumor cells, and
neighboring cells is very complex. Cells are influenced
by the surrounding microenvironment and this process
involves a selection mechanism of tumor cells, which
initiate a number of signaling mechanisms to evade the
immune response, as described in the hypothesis of
immunoediting [16]. Under certain circumstances, this
interaction culminates in the eradication of tumor cells, as
occurs the majority of times, or instead, in suppression of
the immune response and tumor formation. Within this
context, tumor cells developed various escape mechanisms
to avoid NK-mediated killing; tumor cells produced cyto-
kines, growth factors, and enzymes that induced suppres-
sion of cells of the immune response [17,18]. Heme
oxygenase 1 (HO-1) is the rate-limiting enzyme in heme
catabolism and leads to three products: biliverdin; free
iron, and carbon monoxide [19]. It plays an important role
in the modulation of inflammation, blocking the apoptotic
process and antioxidant defense in the presence of any
damage [20,21]. This enzyme is overexpressed in pancre-
atic, colon, and lung cancer, in which it can promote
tumor cell proliferation and resistance to tumor therapy
[22,23]. Induction of HO-1 in tumor cells undergoing any
stressor agent increases their resistance to apoptosis
[24-26]. Likewise, inhibition of this enzyme leads to the re-
duction of tumor growth and an increase in sensitivity to
chemotherapy [19,27]. In this study, we evaluated HO-1 ex-
pression in Cervical cancer cells (CCC) and whether HO-1
inhibition enhanced the sensitivity of CCC to NK cells.
Results
Cervical cancer cell lines express HO-1
We evaluated HO-1 expression in HeLa (HPV 18+),
SiHa (HPV 16+), and C-33A (HPV–) CCC (Figures 1a
and b). We can observe that the HeLa cell is the cancer
cell line that expressed the highest percentage of cells
positive to HO-1 (70.2% ± 4.9%) in comparison with SiHaand C-33A CCC (54.6% ± 1.5% and 30.3% ± 6.5%, respect-
ively) (p <0.01). Additionally, we determined the geometric
Mean fluorescence intensity (MFI) in each cancer cell line.
HeLa, SiHa, and C-33A lines have similar MFI, and we
did not observe a difference for HO-1 MFI among the
three CCC, suggesting that the difference it is not in the
intensity of expression, but rather in the number of cells
positive to HO-1. Likewise, we evaluated viability in CCC
treated with SnPP (25 μM) and ZnPP (1 μM) HO-1 inhibi-
tors and observed that these inhibitors did not affect the
viability in these cells (Figure 1c). In addition, we evaluated
whether HO-1 inhibitors affect the expression of NK cell
ligands, such as MICA and MICB. HeLa and SiHa cells
express MICA, but not MICB, while C-33A expresses
MICB, but not MICA, and we did not observe a change in
MICA or MICB expression when cells were treated with
SnPP or ZnPP inhibitors (Figure 1d). HO-1 inhibitors did
not affect MICA and MICB receptors.
CD107a expression in NK-92 cells co-cultured either with
cervical cancer cells pre-treated or not with the SnPP,
HO-1 inhibitor
We evaluated the expression of CD107a in NK-92 cells
co-cultured with HeLa, SiHa, and C-33A CCC pre-treated
or not with HO-1 inhibitor (SnPP) (Figure 2). In Figure 2a,
we can observe the baseline expression of CD107a in NK-
92 cells and the positive-control PMA/Ionomycin increase
of this expression. We did not observe differences in NK-
92 cells co-cultured with HeLa cells pre-treated or not
with HO-1 inhibitor in all target effector ratios (T:E) 1:5
and 1:20 (Figure 2b). In NK-92 cells co-cultured with SiHa
and C-33A CCC, we observed similar behavior to that ob-
served for HeLa; there were no significant differences be-
tween the different T:E ranges between pre-treated cells or
not treated with the HO-1 inhibitor. When we analyzed
MFI for CD107a, there was no difference in any of the ex-
perimental groups; as we expected, only the positive con-
trol group (PMA+ Ionomycin) increased expression and
MFI of CD107a in NK-92 cells.
Increase of IFN-γ and TNF-α production in NK-92 cells
positive to CD107a co-cultured with cervical cancer cell
lines pre-treated with the HO-1 inhibitor
In Figure 3a, we observe the baseline expression of INF-
γ and TNF-α in CD107a + NK-92 cells (Basal group)
and in the positive control group (PMA/Ionomycin) that
induced degranulation in NK-92 cells. In Figures 3b and
c, we can observe that in NK-92 cells co-cultured with
HeLa cells pre-treated with HO-1 inhibitor SnPP, there
is an increase of IFN-γ production (p <0.05) in compari-
son with HeLa cells without pre-treatment with the HO-
1 inhibitor, in which the highest IFN-γ expression fell
within the range of 1:5. When NK-92 cells were co-
cultured with SiHa cells, we observed a similar effect to
Figure 1 Expression of Heme oxygenase 1 (HO-1) in different Cervical cancer cell (CCC) lines. Expression of HO-1 in HeLa, SiHa, and C-33A
cells was detected by indirect staining protocol using a PE-conjugated anti-mouse secondary antibody after incubation with mouse anti-HO-1
primary antibody. Results represent the mean ± Standard deviation (SD) of three independent experiments carried out in triplicate. A representative
experiment of HO-1 expression in HeLa, SiHa, and C-33A cells is shown (a). Percentage of HO-1 expression in HeLa, SiHa, and C-33A cells (b). After
treatment with HO-1 inhibitors, viability in HeLa, SiHa, and C-33A cells was evaluated with Sytox by Flow cytometry (FC) (c). Expression of MICA and
MICB in HeLa, SiHa, and C-33A cells treated or not with SnPP (25 μM) or ZnPP (1 μM), (HO-1 inhibitors) (d). *P <0.05 HeLa, SiHa vs. C-33A cells.
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IFN-γ expression was observed when SiHa cells were
pre-treated with SnPP (the HO-1 inhibitor) (p <0.05).
When NK-92 cells were co-cultured with C-33A pre-
treated with HO-1 inhibitor, we can observe a significant
increase in the production of IFN-γ in comparison with
C-33A without pre-treatment with the HO-1 inhibitor
(p <0.05). In general, there was an increase in the pro-
duction of IFN-γ in CD107a + NK-92 cells co-cultured
with HeLa, SiHa, and C-33A pre-treated with the HO-1
inhibitor (SnPP). In the same Figure 3b and c, we can
observe TNF-α production in CD107a + NK-92 cells co-
cultured with HeLa, SiHa, and C-33A pre-treated or not
with the HO-1 inhibitor. In the co-culture with HeLa
cells, when tumor cells were pre-treated with the HO-1
inhibitor, TNF-α production was significant in NK-92 cells
(p <0.05). We observed a similar difference in the SiHaco-culture. Production of TNF-α in NK-92 cells co-
cultured with C-33A pre-treated with the HO-1 inhibitor
is significantly increased within the 1:20 range (p <0.05).
Granzyme B expression in CD107a + NK-92 cells co-cultured
with cervical cancer cell lines pre-treated with the HO-1
inhibitor
We evaluated granzyme B expression in CD107a +NK-92
cells co-cultured with HeLa, SiHa, and C-33A CCC pre-
treated or not with the HO-1 inhibitor (Figure 4). We did
not observe differences in granzyme B release in any T:E
ratios 1:5 and (1:20 and 1:40, data not shown) in NK-92
cells co-cultured with HeLa, SiHa, and C-33A CCC pre-
treated or not with the HO-1 inhibitor. It is important to
stress that PMA/Ionomycin induces the release of gran-
zyme B and correlates with the association between

































































Figure 2 Expression of CD107a in NK-92 cells co-cultured with Cervical cancer cells (CCC) pre-treated or not with Heme oxygenase 1
(HO-1) inhibitor. CCC were pre-treated with the HO-1 inhibitor (SnPP) for 48 h; afterward, NK-92 cells were co-cultured with HeLa, SiHa, and C-33A CCC for
4 h. Then, the expression of CD107a was analyzed by Flow cytometry (FC). Expression of CD107a in NK-92 cells and in PMA/Ionomycin groups (a). NK-92/
CCC co-culture (b). PMA/Ionomycin was used as positive control. These data are representative of three independent experiments.
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http://www.cancerci.com/content/14/1/100Supernatant of cervical cancer cell lines HeLa, SiHa, and
C-33A induces downmodulation of NCR and NKG2D
receptors in NK cells
We investigated whether the supernatant of CCC HeLa,
SiHa, and C-33A induces downmodulation of NKp30,
NKp44, NKp46 and NKG2D in NK-92 cell line and NK
cells of healthy donors. We observed that in both cells,
HeLa and SiHa cancer cells induce downmodulation of
NKp30, NKp46, and NKG2D in NK cells, and in C-33A
cells only NKp30 and NKp46 (p <0.05 Figures 5 and 6).
Likewise, in NK-92 cells we observed downmodulation
of NKp44 when the cells were treated with the super-
natant of HeLa and SiHa (p <0.05).
The HO-1 inhibitor restores downmodulation in NCR and
NKG2D expression in NK-92 cells co-cultured with cervical
cancer cell lines
We evaluated the expression of NKp30, NKp44, NKp46,
and NKG2D in NK-92 cells co-cultured with HeLa,SiHa, and C-33A cancer cells pre-treated or not with the
HO-1 inhibitors. We can observe that in NK-92 cells co-
cultured with HeLa cells pre-treated with SnPP (the HO-1
inhibitor), there is an increase in NKG2D, and NKp30 ex-
pression within the different T:E ratios (p <0.05) (Figure 7)
in comparison with HeLa cells without pre-treatment with
the HO-1 inhibitor. When NK-92 cells were co-cultured
with SiHa cells, we observed a similar effect to that ob-
served with HeLa cells, and an increase in NKG2D,
NKp46, and NKp30 receptor when SiHa cells were pre-
treated with SnPP (p <0.05), in comparison with SiHa cells
without pre-treatment. When NK-92 cells were co-
cultured with C-33A pre-treated with the HO-1 inhibitor,
we are able to observe a significant increase in the expres-
sion of NKp46 within the 1:20 ratio (p <0.05) in compari-
son with cells without pre-treatment. We observed similar
and comparable results when we used the ZnPP inhibitor
(data not shown). Similarly, we performed transwell assays
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Figure 3 Increase of Interferon gamma (IFN-γ) and Tumor necrosis factor alpha (TNF-α) in CD107a + NK-92 cells co-cultured with
Cervical cancer cell (CCC) lines pre-treated with Heme oxygenase 1 (HO-1) inhibitor. CCC were pre-treated with HO-1 inhibitor (SnPP) for
48 h; after that, NK-92 cells were co-cultured with HeLa, SiHa, and C-33A CCC for 4 h. Then, the expression of IFN-γ and TNF-α was analyzed in
CD107a + NK-92 cells by Flow cytometry (FC). Expression of IFN-γ and TNF-α in CD107a + NK-92 cells without co-culture and in NK-92 cells
stimulated with PMA/Ionomycin (positive control), gray profiles represent isotype controls (a). A representative experimental of IFN-γ and TNF-α
production in CD107a + Natural killer (NK)-92/CCC co-culture (b). The percentage of IFN-γ and TNF-α production in CD107a + NK-92/CCC
co-culture (c). Bars represent the mean ± Standard deviation (SD) of three independent experiments carried out in triplicate. *P <0.05 1:5 + SnPP
or 1:20 + SnPP vs. 1:5 or 1:20 in HeLa, SiHa, and C-33A. Mann–Whitney U test.
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http://www.cancerci.com/content/14/1/100NK-92 and NK cells of healthy donors. We can observe, in
Table 1, that the greatest change observed was in NKp30
and NKG2D receptors in HeLa and SiHa cells, and that
when NK-92 cells were treated with HO-1 inhibitors (SnPP
and ZnPP), this downmodulation is partially recovered (p
<0.05). We observed similar results with NK primary cells
of healthy donors (data not shown).
Discussion
Tumor cells acquire different capabilities that allow them
to grow uncontrollably and even to evade the immune re-
sponse. Among these acquired skills, we find the expres-
sion of certain cytokines, chemokines, and enzymes that
are not normally expressed and that can facilitate an eva-
sion of this type, such as Transforming growth factor beta(TGF-β), Interleukin (IL)-10, Prostaglandin E2 (PGE2),
and indoleamine 2,3-dioxygenase [28]. In this regard, HO-
1 possesses an important immune protective effect [29].
This enzyme is vital for the removal of heme, a potent
pro-oxidant and inflammatory agent. HO-1 induces heme
degradation and produces three metabolites: CO; ferrous
iron, and biliverdin, all these metabolites with an immune
protective effect [30]. We show that CCC HeLa, SiHa, and
C-33A express HO-1; while each cell has a different per-
centage of expression of HO-1, all possess a similar
amount of HO-1 (MFI were similar in HeLa, SiHa, and C-
33A cells). The expression of HO-1 has been associated
with anti-apoptotic and anti-inflammatory effects [31]. In
this respect, it was published that HO-1 can induce the


























Figure 4 Expression of granzyme B in CD107a + NK92 cells co-cultured with Cervical cancer cell (CCC) lines pre-treated or not with
the Heme oxygenase 1 (HO-1) inhibitor. CCC were pre-treated with the HO-1 inhibitor (SnPP) for 48 h; afterward, NK-92 cells were co-cultured with
CCC for 4 h. Then, the expression of granzyme B was analyzed in CD107a +NK-92 cells co-cultured with HeLA, SiHa, and C-33A pre-treated or not with the
SnPP by Flow cytometry (FC). A representative experiment is shown.
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http://www.cancerci.com/content/14/1/100the immune response [32,33]. Overexpression of HO-1
has been reported in many cancer types, such as colorec-
tal, pancreatic, and prostate [34]. Likewise, it was pub-
lished that HO-1 is involved in macrophage polarization
toward an M2 phenotype [35], and that HO-1+ macro-
phages induce suppression of the immune response
[36]. In this regard, it was also observed that HO-1
expressed by dendritic cells favors the emergence of
CD4 + CD25+ regulatory T cells and inhibits the prolif-
eration of T cells [37]. NK cells comprise the major cells
involved in early responses against infected and tumor
cells [38]. CD107a is associated with lysosomal mem-
branes and has been associated with the degranulation
of NK cells and CD8+ T cells, having been adopted as a
marker of activation due to the association between the
increased expression and increased cytotoxicity of their
target cells [39,40]. In our studies, we did not observe a
change in the expression of CD107a in NK cells co-
cultured with HeLa, SiHa, or C-33A CCC pre-treated or
not with the HO-1 inhibitor (SnPP), although we did ob-
serve an increase in the production of TNF-α and IFN-γ
in CD107a +NK-92 cells co-cultured with cancer cells
pre-treated with the HO-1 inhibitor. In this regard, in our
study, when NK cells were co-cultured with HeLa, SiHa,
and C-33A CCC pre-treated or not with the HO-1inhibitor (SnPP), we did not observe a difference in the ex-
pression of CD107a and granzyme B in NK-92 cells. Al-
though HeLa, SiHa, and C-33A cells express HO-1, this
enzyme does not participate in the blocking of NK cell de-
granulation, because pre-treatment with the inhibitor of
the enzyme does not induce changes in CD107a expres-
sion. Suppression of cytotoxicity in NK cells is associated
with an important reduction in CD107a surface expression
and suppression of granzyme B release [41]. It is likely that
HO-1 does not interfere or intervene with the process of
NK cell degranulation and cytotoxicity. It is noteworthy
that CCC HeLa, SiHa, and C-33A, through other mole-
cules, could interfere with the degranulation and cytotox-
icity process in NK cells, as has been demonstrated with
PGE2 [10], although we observed a significant increase of
CD107a expression and cytotoxicity in K562 using NK-92
cells, and CD107a upregulation correlates with lysis of the
target cells (data not shown). The cytotoxic action of NK
cells comprises a series of steps involving combining the
adhesion, activation, and secretion of lytic granules
and other molecules, and NK cytotoxicity results are
dependent on several changes that occur, such as
phenotypical, functional, and molecular. While CD107a
expression may not necessarily correlate with NK cytotox-





























































































Basal   HeLa   SiHa   C-33A Basal   HeLa   SiHa   C-33A
Basal   HeLa   SiHa   C-33A Basal   HeLa   SiHa   C-33A
Basal   HeLa   SiHa   C-33A Basal   HeLa   SiHa   C-33A
Basal   HeLa   SiHa   C-33A Basal   HeLa   SiHa   C-33A
*
Figure 5 Downmodulation of NCR and NKG2D in NK-92 cells treated with the supernatant of HeLa, SiHa, and C-33A Cervical cancer
cells (CCC). Supernatant of CCC was added to a final concentration of 30% in NK-92 cells. Then, the cells were incubated for 24 h at 37°C in a
humid atmosphere containing 5% CO2 and 95% air in RPMI-S medium. Afterward, the expression of NCR or NKG2D was analyzed by Flow cytometry
(FC). Values of percentage of expression and geometric Mean fluorescence intensity (MFI) for NKp30, NKp44, NKp46, and NKG2D in NK-92 cells treated or
not with the supernatant of HeLa, SiHa, and C-33A CCC. Results are represented as the mean ± Standard deviation (SD) of three independent experiments
performed in triplicate. *P <0.05 HeLa, SiHa, and C-33A vs. basal group, or HeLa, SiHa vs. basal group, Mann–Whitney U test.
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http://www.cancerci.com/content/14/1/100mechanisms, such as FasL and TRAIL [42,43]. Previous
studies demonstrated that products of the heme catabol-
ism, such as CO, induced, in T cells, a reduction in IL-2
secretion and proliferation of the cells via inhibition of the
ERK MAPK pathway [44]. Similarly, the use the metabo-
lites induced by the action of HO-1 on a heme group, such
as CO, ferritin, or bilirubin alone or in combination, in-
duces a decrease in the production of TNF-α, IL-1, IL-6,
and IFN-γ, and instead promotes IL-10 production
[45,46]. It was in our interest to investigate whether inhib-
ition of HO-1 in tumor cells increased the production of
IFN-γ and TNF-α in the population of CD107a +NK-92
cells in our study. We observed that inhibition of the en-
zyme HO-1 increased IFN-γ and TNF-α expression in
NK-92 cells co-cultured with HeLa, SiHa, and C-33A cells
pre-treated with the HO-1 inhibitor. We observed, in SiHa
(HPV 16+) cells pre-treated with the HO-1 inhibitor, a
strong increase in IFN-γ and TNF-α production,indicating that the HPV may play a role in blocking the
production of these cytokines in NK cells. The effect ob-
served when we employed the HO-1 inhibitor on IFN-γ
and TNF-α production in CD107a +NK-92 cells co-
cultured with CCC was important because IFN-γ and
TNF-α produced by NK cells can induce apoptosis in
tumor cells by means of interaction with localized cell-
death receptors in tumor cells or through stimulation of
cytotoxicity activity in CD8+ cells, in addition to helping
to differentiate CD4+ T cells toward a Th1 response to
promote CD8+ cell differentiation and to promote antitu-
mor antibody production by B cells [47-50]. In addition,
soluble E6 and E7 oncoproteins of HPV-16 inhibit NK
cells to produce IFN [51]. Activating receptors are very
important in NK activity, and it was reported that tumor
cells can induce a decrease in the expression of activation
receptors in NK cells, the latter through several mecha-
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Figure 6 Downmodulation of NCR and NKG2D in NK cells treated with the supernatant of HeLa, SiHa, and C-33A Cervical cancer cells (CCC).
Supernatant of CCC was added to a final concentration of 30% in primary NK cells of healthy donors. Then, the cells were incubated for 24 h at 37°C in a
humid atmosphere containing 5% CO2 and 95% air in RPMI-S medium. Afterward, the expression of NCR or NKG2D was analyzed by Flow cytometry
(FC). Values of percentage of expression and geometric Mean fluorescence intensity (MFI) for NKp30, NKp44, NKp46, and NKG2D in NK cells treated or not
with the supernatant of HeLa, SiHa, and C-33A CCC. Results are represented as the mean ± Standard deviation (SD) of three independent experiments
performed in triplicate. *P <0.05 HeLa, SiHa, and C-33A vs. basal group, or HeLa, SiHa vs. basal group, Mann–Whitney U test.
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http://www.cancerci.com/content/14/1/100receptor and disrupting the binding between the activating
receptor and the ligand expressed by tumor cells or by in-
ducing the internalization of the activating receptor on
NK cells [52,53]. In another study, we showed that CCC
can induce downmodulation of the NKG2D receptor [54].
This is important because we observed that when HeLa
and SiHa cells were pre-treated with the HO-1 inhibitors
(SnPP and ZnPP) and subsequently co-cultured with NK-
92 cells, the downmodulated expression of NKG2D and
NKp30 was restored, in comparison with NK-92 cells co-
cultured with HeLa and SiHa CCC without pre-treatment
with HO-1 inhibitors. This same phenomenon was ob-
served for NKp46 in HeLa, SiHa and C-33A cells. We ob-
served a similar response in NK cells of healthy donors
(data not shown). All data strengthened the importance of
HO-1 in this phenomenon because we observed these ef-
fects when we employed both HO-1 inhibitors. It is note-
worthy that we also observed a significant decrease in NK-92 and primary NK cells in the expression of NKp30,
NKp46, and NKG2D after 24 h of their being exposed to
the culture supernatant of HeLa, SiHa, and C-33A CCC.
NK cells are found in the stroma of HPV-infected Cervical
intraepithelial neoplasia (CIN); however, NKp30, NKp46,
and NKG2D expression is reduced in patients with pre-
cancerous or cancerous HPV-induced lesions and, in
addition, their cytotoxicity was reduced [51,55].
We also studied the regulation of some NK cell li-
gands, such as MICA and MICB, in CCC and the effect
of HO-1 inhibitors on their expression. However, we
did not observe any change in MICA and MICB expres-
sion when we utilized HO-1 inhibitors. MICA is high
expressed in HeLa and SiHa cells, but MICB is absent.
In C-33A, we found higher expression of MICB in com-
parison with HeLa and SiHa cells. At present, we are
studying whether HO-1 inhibitors exert some effect on
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Figure 7 Downmodulation of NKG2D, NKp46, and NKp30 in NK-92 cells co-cultured with Cervical cancer cell (CCC) lines. CCC were
pre-treated with the Heme oxygenase 1 (HO-1) inhibitor (SnPP) for 48 h; after that, NK-92 cells were co-cultured with HeLa, SiHa, and C-33A CCC
for 4 h. Then, the expression of NKp30, NKp44, NKp46, and NKG2D was analyzed in NK-92 cells by Flow cytometry (FC). Expression of NKp30,
NKp44, NKp46, and NKG2D in NK-92 (Basal group) (a). Expression of NKp30, NKp44, NKp46, and NKG2D in NK92/HeLa cell co-culture (b). Expression of
NKp30, NKp44, NKp46, and NKG2D in NK92/SiHa cell co-cultures (c). Expression of NKp30, NKp44, NKp46, and NKG2D in NK92/C-33A cell co-cultures
(d). Bars represent the mean ± Standard deviation (SD). Results are represented as the mean ± Standard deviation (SD) of three independent
experiments performed in triplicate. *P <0.05 1:5 + SnPP or 1:20 + SnPP vs. 1:5 or 1:20 in NKG2D, NKp46, and NKP30 in HeLa, SiHa, or C-33A.
Mann–Whitney U test.
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http://www.cancerci.com/content/14/1/100possess several mechanisms to avoid the immune re-
sponse, including the production of molecules with sup-
pressor activity on the immune response; tumor cells
are able to induce a regulatory phenotype in immune
cells, promoting immune evasion. The difference ob-
served in our study among HeLa, SiHa, and C-33A cells
in IFN-γ, TNF-α, NCR, and NKG2D on NK cells indi-
cates that several mechanisms of resistance to cytotox-
icity and to NK cell activity could be implicated, such as
HPV type and their interactions with NK cells. Our
findings indicate that HO-1 can interfere with IFN-γ
and TNF-α production and that are implicated in de-
regulation in the expression of activation receptors such
as NKG2D, NKp30, and NKp46.Conclusions
HO-1 inhibition in cervical cancer cells HeLa, SiHa, and
C-33A induce an increase in IFN-γ and TNF-α production
in CD107a + NK-92 cells and restore downmodulation
of NKG2D, NKp30, and NKp46 in NK cells. These re-
sults demonstrate the complexity in the different inter-
relations between cancer cells and immune cells. The
interactions in the tumor microenvironment should be
considered before designing NK cell therapies.
Methods
Antibodies and reagents
The following mAbs were used in this study: mouse-anti-
human-IFN-γ-PE/Cy7 [BioLegend, San Diego, CA, USA);
Table 1 Downmodulation of NCR and NKG2D in NK-92
cells co-cultured with Cervical cancer cell (CCC) lines
Hela SiHa C-33A
NKG2D
Basal 2235 2235 2235
Without HO-1 Inhibitor 1690 1830 2110
SnPP 2145* 2050* 2198
ZnPP 2189* 2012* 2241
NKp30
Basal 2127 2127 2127
Without HO-1 Inhibitor 888 1609 1658
SnPP* 1848 1949 2087
ZnPP* 1929 1893 1989
NKp44
Basal 2025 2025 2025
Without HO-1 Inhibitor 1684 1801 2090
SnPP 2110* 2087* 2089
ZnPP 1989* 2046* 2105
NKp46
Basal 1900 1900 1900
Without HO-1 Inhibitor 1500 1588 1610
SnPP* 1925 2043 1892
ZnPP* 1875 1984 1931
CCC HeLa, SiHa, and C-33A were pre-treated with SnPP or ZnPP HO-1 inhibitors.
Afterward, transwell assays were performed between NK-92 cells and HeLa, SiHa,
and C-33A. Subsequently, the geometric Mean fluorescence intensity (MIF) of
NKG2D, NKp30, NKp44, and NKp46 were determined. The Standard deviation
(SD) of MIF in all groups did not exceed 135. *P <0.05 SnPP- or ZnPP-treated CCC
vs. HeLa, SiHa, and C-33A without treatment.




gend, clone:H4A3]; mouse-anti-human-granzyme B-AF647
[BioLegend, clone:GB11]; mouse-anti-human-TNF-γ-PE/
Cy7 [BioLegend, clone:MAb11]; mouse-anti-human-HO1
(Abcam, Cambridge, MA, USA); goat-anti-mouse-IgG-PE
(Abcam); mouse-anti-human-MICA-PE [R&D systems,
Mineapolis, MN, USA; clone:159227] and mouse-anti-hu-
man-MICB-APC [R&D systems, clone:236511]. LIVE/
DEAD Fixable Near-IR (Invitrogen, Life Technologies,
Grand Island, NY, USA), and SYTOX Red Dead Cells
Stain (Invitrogen, Life Tchnologies). Zinc and Tin-
protoporphyrin IX (ZnPP and SnPP, HO-1 inhibitors) was
purchased from Frontier Scientific, Inc. (Logan, UT, USA).
A stock solution was prepared in DMSO and protected
from light. CCC were treated with the HO-1 inhibitor
(SnPP) at a final concentration of 25 μM during 48 h and
with Zinc protoporphyrin (ZnPP) at a final concentration
of 1 μM. Viability and MICA and MICB expression were
evaluated using SYTOX and MICA and MICB antibodies,respectively. The final concentration of DMSO in the cell
culture medium was <0.1%.
Cell lines
HeLa (HPV-18+), SiHa (HPV-16+), and C-33A (HPV–)
CCC were kindly provided by Dr. Boukamp (DKFZH,
Heidelberg, Germany). The presence of HPV type was
confirmed by the Linear array genotyping test (Roche).
NK-92 cells were obtained from American Type Culture
Collection (ATCC CRL-2407™; Manassas, VA, USA).
Blood of healthy donors was obtained with informed
consent and NK primary cells were isolated using FAC-
SAria I cell sorting (BD Biosciences, San Jose, CA, USA).
The CCC (HeLa, SiHa, and C-33A) were maintained
in vitro propagated in Dulbecco’s modified Eagle’s culture
medium (DMEM; GIBCO™ Invitrogen Corp., Carlsbad,
CA, USA) with 10% heat-inactivated Fetal bovine serum
(FBS; GIBCO™ Invitrogen Corp.), and NK-92 cells were
maintained in vitro propagated in RPMI-1640 culture
medium (GIBCO™ Invitrogen Corp.) with 100 U/mL re-
combinant human IL-2 (BioLegend) and FBS at a final
concentration of 15% (GIBCO™ Invitrogen Corp.); both
media were supplemented with 1X L-glutamine (at a 2-
mM final concentration; GIBCO™ Invitrogen Corp.) and
antibiotics (penicillin/streptomycin; GIBCO™ Invitrogen
Corp.). These media will be referred to as DMEM-S and
RPMI-S. Cells were incubated at 37°C in a humidified at-
mosphere containing 95% air and 5% CO2.
Supernatant of cervical cancer cell lines
CCC HeLa, SiHa, and C-33A were grown in flasks at
80–90% confluence and harvested with trypsin. After
that, 100,000 HeLa, SiHa, or C-33A cells were plated on
2 mL of DMEM-S on 6-well culture plates. Cells were
incubated at 37°C in a humidified atmosphere contain-
ing 95% air and 5% CO2 for 5 days. Afterward, the cul-
tured supernatant of these cell lines was collected, and
NK-92 and NK primary cells were treated or not with
the supernatant of HeLa, SiHa and C-33A at a final con-
centration of 30% of the total volume. Subsequently, the
cells were incubated for 24 h in a humidified atmosphere
containing 95% air and 5% CO2.
Evaluation of HO-1 expression on cervical cancer cell lines
Expression of HO-1 in HeLa, SiHa, and C-33A CCC lines
was detected by an indirect staining protocol using a PE-
conjugated anti-mouse secondary antibody after incubation
with mouse anti-HO-1 primary antibody (Abcam). At least
10,000 events were acquired using an EPICS XL-MCL™
Beckman Coulter model flow cytometer (Fullerton, CA,
USA). Data were processed with FlowJo ver. X.0.7 software
(Tree Star, Inc., Ashland, OR, USA) and results are re-
ported as the % of expression or geometric Mean fluor-
escence intensity (MFI).
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NK cells were co-cultured with HeLa, SiHa, and C-33A
CCC pre-treated or not with HO-1 inhibitors (SnPP or
ZnPP). Briefly, HeLa, SiHa, and C-33A cells (20,000) were
seeded in U-bottom 96-well plates and then were placed in
contact with NK-92 cells or NK primary cells at T:E (Tar-
get [CCC]:Effector cells [NK cells]) at ratios of 1:5, 1:20,
and 1:40; we used PMA+ Ionomycin as positive control
[40]. Then we added anti-CD107a-FITC. Subsequently, the
cells were incubated for 1 h at 37°C in a humidified atmos-
phere containing 95% air and 5% CO2. Afterward, we
added the protein transport inhibitors Brefeldin A (BioLe-
gend) at a final dilution of 1/1,000 and Monensin (Sigma
Chemical Co., St. Louis, MO, USA) at a final concentration
of 6 μg/mL. Then, the cells were cultured for 4 h at 37°C
in a humidified atmosphere containing 95% air and 5%
CO2. Afterward, we evaluated CD107a, TNF-α, IFN-γ,
granzyme B, NKp30, NKp44, NKp46, and NKG2D expres-
sion in NK cells by Flow cytometry (FC).
Transwell assay
CCC HeLa, SiHa, and C-33A were cultured with NK-92
and NK primary cells in a dual-chamber transwell (0.4-μm
micropores; Costar, Corning, NY, USA). NK cells were
placed into the lower chamber and CCC were placed into
the upper chamber and were cultured at 37°C for 24 h. After
that, the NK cells were collected and we evaluated NCR and
NKG2D expression.
Assessment of CD107a, TNF-α, IFN-γ, and granzyme B by
flow cytometry
After the co-culture, we determined CD107a, TNF-α, IFN-γ
and granzyme B (BioLegend) by FC. First, NK-92 cells were
stain for viability using LIVE/DEAD Fixable Near-IR. After
that NK-92 cells were harvested and resuspended in PBS,
stained with CD56-PE, and incubated in the dark for 30 min
at room temperature. Afterward, the cells were washed and
fixed with fixation buffer (BioLegend) for 15 min. Then, the
cells were washed and permeabilized with permeabilization
buffer 1X (BioLegend), we added TNF-γ-PE-Cy7, granzyme
B-AF647, or IFN-α-PE-Cy7, and the cells were incubated in
the dark for 30 min. Then, the cells were washed with PBS,
fixed with paraformaldehyde 1 %, and analyzed by FC. An
appropriate isotype and Fluorescence Minus One (FMO)
controls were utilized to adjust for background fluorescence,
and results are reported as the % of expression. For each
sample, at least 10,000 events were acquired in a FACSAria
I cell sorter (BD Biosciences). Data were processed with
FlowJo ver. X.0.7 software (Tree Star, Inc.).
Assessment of NKp30, NKp44, NKp46, and NKG2D by flow
cytometry
After co-culture, we evaluated the expression of NKp30,
NKp44, NKp46, and NKG2D in NK cells by FC. First,NK cells were stain for viability using LIVE/DEAD Fixable
Near-IR, after that NK cells were harvested, resuspended
in PBS, and stained with CD56-APC, NKp30-PE, NKp44-
PE, NKp46-PE, or NKG2D-PE (BioLegend); subsequently,
the cells were incubated in the dark for 30 min at room
temperature. Cells were washed and fixed with parafor-
maldehyde 1%. An appropriate isotype and FMO controls
were utilized to adjust for background fluorescence, and
results are reported as the % of expression or geometric
Mean fluorescence intensity (MFI). For each sample, at
least 10,000 events were acquired in a FACSAria I cell
sorter (BD Bioscience). Data were processed with FlowJo
ver. X.0.7 software (Tree Star, Inc.).
Statistical analysis
All experiments were carried out in triplicate and were re-
peated three times. The values represent mean ± Standard
deviation (SD) of the values obtained. Statistical analysis
was performed with the non-parametric Mann–Whitney
U test, considering p <0.05 as significant.
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